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Magnetic nanoparticle transport within flowing 
blood and into surrounding tissue
In magnetic drug targeting, magnetic particles 
containing or coated with therapeutics are con­
centrated to sites of disease by applied magnetic 
fields. This has allowed focusing of chemo­
therapy to solid tumors in Phase I human clini­
cal trials [1], and in animal experiments [2–5], and 
is being used to target drugs to other types of 
disease locations (e.g., to regions of thrombo­
sis [6]). During such treatments, magnetic par­
ticles are usually injected into the bloodstream, 
and magnets are then used to concentrate them 
to target locations. There is a need to know 
which locations can or cannot be effectively 
reached by magnetic drug targeting. Key issues 
include whether the applied magnetic forces can 
hold particles against blood flow, at which body 
depth, in which blood vessels, and how far par­
ticles subsequently travel from the vessels into 
surrounding tissue.
Physical parameters, such as particle size and 
materials, as well as magnet placement, size, 
shape and strength, are crucial for the success 
of magnetic drug focusing. However, there is 
little ability to predict how these parameters will 
affect particle behavior in vivo. This has forced 
critical magnetic drug delivery design choices to 
be made based on intuition, empirical data and 
simple engineering estimates – and these rough 
tools are proving insufficient. For example, the 
question of whether magnets can or cannot 
hold nanoparticles against blood flow is often 
addressed when designing experiments by com­
paring the maximum force that the blood flow 
exerts on a particle against the applied magnetic 
force. This analysis underpredicts the ability of 
a magnetic field to hold particles against blood 
flow, and does not match behavior observed in 
animal experiments. In rats, the slowest blood 
flow velocity, in capillaries, has been measured to 
be approxiately 0.1 mm/s [7], a velocity that will 
create a (Stokes) drag force [8] of F
blood
 ≈ 7 × 10­13 
Newtons on a 250 nm diameter particle at the 
vessel center. For the rat experiments shown 
in Figure 1, a 0.5 Tesla, 5 cm long, 5 mm wide 
permanent magnet was used to concentrate 
250 nm diameter iron oxide nanoparticles 
underneath the skin against blood flow. The 
magnetic field created by this magnet, and the 
resulting magnetic force [8], works out to be only 
F
mag
 ≈ 1 × 10­13 Newtons, a factor of a seventh 
smaller. This calculation suggests that blood 
flow forces will overcome the applied magnetic 
forces; yet, magnetic drug focusing was clearly 
observed, as shown in Figure 1. This experiment 
was repeated for 100 nm particles, in which case 
the magnetic force is 109 times smaller than the 
vessel centerline blood drag force, yet focusing 
remained successful.
Magnetic drug delivery refers to the physical confinement of therapeutic magnetic nanoparticles to 
regions of disease, tumors, infections and blood clots. Predicting the effectiveness of magnetic focusing 
in vivo is critical for the design and use of magnetic drug delivery systems. However, current simple 
back-of-the-envelope estimates have proven insufficient for this task. In this article, we present an 
analysis of nanoparticle distribution, in and around a single blood vessel (a Krogh tissue cylinder), 
located at any depth in the body, with any physiologically relevant blood flow velocity, diffusion and 
extravasation properties, and with any applied magnetic force on the particles. For any such blood 
vessel our analysis predicts one of three distinct types of particle behavior (velocity dominated, 
magnetic dominated or boundary-layer formation), which can be uniquely determined by looking up 
the values of three nondimensional numbers we define. We compare our predictions to previously 
published magnetic-focusing in vitro and in vivo studies. Not only do we find agreement between our 
predictions and prior observations, but we are also able to quantitatively explain behavior that was 
not understood previously.
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Methods
As shown in Figure 2B, we focus our attention on 
nanoparticle behavior in and around a single 
blood vessel (a Krogh tissue cylinder geometry [9]). 
This blood vessel can be of any type, from a major 
artery or a vein, to a minor capillary, fenestrated 
or not, at any depth, and any applied magnetic 
force can be considered. Instead of using simple 
engineering estimates, starting from physical first 
principles, we state and then solve the equations 
governing the diffusion, convection and magnetic 
transport of nanoparticles in the blood and into 
surrounding tissue. These equations describe the 
time progression of the nanoparticle concentra­
tion at every spatial location in the blood and sur­
rounding tissue. The first equation captures par­
ticle transport due to convection by blood flow, 
particle diffusion (including particle scattering 
by collisions with blood cells [10]), and particle 
motion due to magnetic forces (see [11] for details).
Here, C
B
 is the concentration of particles at each 
location in the blood, VB<  is the blood velocity, 
t is time, ∇ is the gradient operator, and Pe 
and Y are the Péclet and magnetic­Richardson 
numbers. The next two equations include diffu­
sion and transport in the endothelial membrane 
and surrounding tissue. This type of formula­
tion is standard, and, as in [9], extravasation 
(or lack thereof) is modeled by adjusting the 
diffusion coefficient in the endothelium, D, 
to a nonzero (or zero) value. Additional tis­
sue­specific properties, for example, decreased 
resistance to nanoparticle motion owing to a 
compromised extracellular matrix with larger 
interstitial spaces in a tumor region, can be 
accounted for by decreasing the magnetic drift 
coefficient (the magnetic­Richardson number), 
Y, in that region. Increased interstitial tumor 
pressure can decrease blood flow velocity into 
a tumor and, therefore, is reflected by choosing 
an appropriately lower V
Bmax
 velocity in affected 
blood vessels.
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 and C
T
 are the concentrations of particles 
at every location in the endothelial membrane 
and tissue, and D and D
T
 are the endothe­
lium and tissue Renkin­reduced diffusion coef­
ficients. As shown in Figure 2B, it is assumed 
that the blood vessel is aligned perpendicularly 
to the applied magnetic force. If the vessel is 
at an angle to the magnetic force, then only 
the perpendicular part of the force should be 
used for F
M
 below, and the tangential part can 
be added to the drag forces along the blood 
vessel, to F
S
. These equations are stated in 
Figure 2. simulation domain. (A) Magnetic drug focusing in Phase I human clinical trials [1]. 
(B) We consider a single blood vessel (of any size, depth and blood velocity) and surrounding tissue 
and analyze the spatial distribution of magnetic particles.  
(A) Adapted with permission from A Lübbe (Medical Center for Health, Bad Lippspringe, Germany).
Figure 1. rat experiments. (A) The 0.5 T magnet and (B) concentrated ferrofluid 
is visible under the skin after treatment [15].
Figure adapted with permission from C Bergemann (Chemicell, Berlin, Germany) 
and A Lübbe (Medical Center for Health, Bad Lippspringe, Germany).
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nondimensional variables, meaning the vari­
ables used have been chosen to highlight the 
competition between phenomena: between 
blood drag and magnetic forces, and between 
diffusion in the blood and surrounding tissue. 
This nondimensional scaling reveals the key 
numbers Y, D, D
T
 and Pe, which uniquely 
determine particle behavior [11]. 
Specifically, the magnetic­Richardson num­
ber, Y, quantifies the ratio between the applied 
magnetic forces and the maximum drag forces 
that the blood in that vessel can exert on the 
nanoparticles. We define it as the ratio: 
Y
Strokesdragforceatcenterline
Magnetic forceat vesselcenterline
F
F
V
V
maxS
M
B
R
<
< << <
= = =
The magnetic force depends both on the 
magnetic field H<  (units: A/m) created by the 
magnet and its spatial gradient /dH dx< <6 @ (A/m2), 
and both must be known at the vessel location 
to compute the magnetic force (see [11] and 
Supplementary Figure 1 [www.futuremedicine.com/
doi/suppl/10.2217/nnm.10.104]). In equation 3, 
VR
<  is the equilibrium velocity (m/s) of the 
nanoparticle created by the applied magnetic 
force. To compute Y, as well as D, D
T
 and Pe, 
all variables should be stated in SI units (e.g., as 
a = 10­7 m for a 100 nm radius particle, then all 
units will exactly cancel, yielding the four non­
dimensional numbers; see the detailed instruc­
tions in the supplementary material and in [11]). 
As the magnetic­Richardson number increases 
beyond 1, the magnetic force exceeds the blood 
drag force at the vessel centerline. Thus, the 
Richardson number is a key indicator of the suc­
cess of magnetic drug focusing, but, as noted 
previously, magnetic focusing can occur even if 
this number is substantially below 1 (as in the 
rat example). 
The second key number that determines the 
success of magnetic drug delivery is the mass 
Péclet number [12]. It quantifies the competi­
tion between particle movement (convection) 
by blood flow versus particle diffusion in the 
blood, and is defined as:
maximum
Total diffusion coefficient of particles
Blood vesselwidth blood velocity
Pe
D
d V max
Tot
B B#= =
Here, D
Tot
 (in m2/s) takes into account the scat­
tering of nanoparticles by collisions with blood 
cells, an effect that can be modeled as additional 
diffusion [10]. For 250 nm diameter particles in rat 
capillaries, Pe ≈ 1000, meaning nanoparticles are 
convected much faster than they diffuse. 
Finally, the Renkin­reduced diffusion coef­
ficients [9], for the endothelium membrane and 
the surrounding tissue, are defined as:
D
Totaldiffusioncoefficient in blood
Diffusioncoefficient inmembrane
D D
D
D
D
B S
M
Tot
M= =
+
=
D
Totaldiffusioncoefficient in blood
Diffusioncoefficient in tissue
D
D
T
Tot
T= =
where D
B
 is the particle diffusion in blood caused 
by thermal fluctuations, D
S
 is the additional dif­
fusion caused by collision with blood cells, D
M
 
is the diffusion in the endothelial membrane (it 
is set to zero if there is no extravasation), and D
T
 
is the particle diffusion in surrounding tissue 
(all in units m2/s). As an example, for 250 nm 
diameter particles, leaky tumor rat capillaries 
with fenestrations on the order of 600 nm have 
a membrane Renkin coefficient of D ≈ 0.36; for 
a tumor extracellular spacing of 1 µm, the tissue 
Renkin coefficient is D
T
 ≈ 0.56 [9].
Under physiological conditions, for vessel 
diameters and blood velocities ranging from 
d
B
= 6 µm and V
Bmax
= 0.1 mm/s (rat capillaries) to 
d
B
 = 3 cm and V
Bmax
 = 40 cm/s (human aorta), and 
for achievable physical parameters, particle diame­
ters ranging from 1 nm to 5 µm, and magnet field 
strengths no greater than 4 Tesla (MRI strengths), 
the four nondimensional parameters can range 
between 4 × 10­18 ≤ Y ≤ 6 × 103, 1 ≤ Pe ≤ 1 × 1012, 
and 0 ≤ min(D, D
T
) ≤ 1 (it suffices to consider 
the minimum of the two Renkin coefficients, as 
the smaller coefficient determines the behavior). 
To map nanoparticle behaviors across this entire 
parameter space, we first divided our nondimen­
sional number space (i.e., Richardson, Péclet and 
Renkin) into a coarse 7 × 7 × 5 grid, and car­
ried out a simulation of particle behavior at each 
number triplet (a total of 245 simulations). This 
revealed the three types of behaviors shown in 
Figure 3 and discussed next. To identify more pre­
cisely the boundaries between these three behavior 
types, we carried out 475 further simulations on 
a finer grid, which spanned the transitions from 
one type of behavior to another.
For each Richardson–Péclet–Renkin triplet, 
we evaluated the transient and final concentra­
tion of nanoparticles, in the blood, endothelial 
membrane and surrounding tissue, accord­
ing to equationS 1 & 2. Initially, this was done 
using the commercial multiphysics package 
COMSOL [101], a package that has been used 
fairly commonly in the magnetic drug delivery 
literature for its ability to couple partial differen­
tial equations. In the numerical methods com­
munity, it is well known that high Péclet number 
cases are extremely difficult to solve; COMSOL 
(3)
(4)
(6)
(5)
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failed to solve cases for Pe values greater than 
1300. To achieve the solutions for Pe numbers 
as high as 1012, we developed and implemented 
a sophisticated inhouse numerical method. Our 
resulting vessel–membrane–tissue (VMT) solver 
for the partial differential equationS 1 & 2 is based on 
a combination of the following four techniques:
  Factorization of the differential operator as a 
product of 1D differential operators and effi­
cient solution of the corresponding ordinary 
differential equations at every time step (the 
ADI method [13]);
  Use of a graded mesh in the vessel domain; 
  Use of changes of unknowns that transform 
the spatial operators in the membrane and tis­
sue domains into operators of Helmholtz type, 
which enables the use of highly optimized 
steady­state solvers; 
  An on­and­off fluid­freezing methodology 
designed to effectively resolve the large time­
scale separation between the dynamics in the 
blood domain and the much slower diffusion 
processes in the membrane and tissue. 
The details underlying the VMT solver can be 
found in [11], and a future contribution in [Beni 
et al., Manuscript in Preparation]. The VMT solver 
was both more accurate and 500 times faster than 
COMSOL, and it was able to solve cases that 
COMSOL could not. Our recent work shows that 
significant further improvements of the algorithm 
are feasible [Beni et al., Manuscript in Preparation].
The VMT simulations predicted nanoparticle 
behavior for any scenario within the considered 
range of physiological/feasible circumstances. 
For any blood vessel, at any body depth, with any 
diameter, and blood flow velocity, for nanoparti­
cles of any size and material properties under any 
applied magnetic field, there is a corresponding 
nondimensional number triplet (Richardson–
Péclet–Renkin), given by equationS 3–6, which 
uniquely determines nanoparticle behavior in 
and around that blood vessel. By looking up 
the behavior of that triplet on our grid of 720 
conducted simulations, we predicted the type of 
behavior (FigureS 3 & 4), and compared it against 
available in vitro and in vivo magnetic drug 
delivery experiments. We found excellent agree­
ment (Figure 5) and were able to explain observed 
behavior that was not p reviously understood. 
results & discussion
Magnetic nanoparticles travel through the blood 
and into the surrounding tissue under three com­
peting effects: under blood convection, diffusion 
N S N S N S
Velocity dominated
Concentration Concentration Concentration
0 0.99 1 1.01 2.5 0 0.99 1 1.01 2.5
Magnetic dominated
Concentration at steady state (for Pe = 333)
Blood
vessel
Endothelial layer
Tissue
log(1) log(1000)
Boundary layer formation
log(C)
0 1 2 3
Particle concentration
0.99 0.996 1.004 1.01
Particle concentration
0.99 0.996 1.004 1.01
Particle concentration
C C
Figure 3. The three behaviors. (A) Velocity dominated, (B) magnetic dominated and (C) a boundary layer formation. In each of the 
three panels, the top, middle and bottom layers show a cross-section through the blood vessel, endothelial layer and surrounding tissue, 
respectively; the equilibrium distribution of nanoparticles is shown by the coloring (white = low; black = high; but case (C) is shown in a 
log scale); and the blue curve on the right shows the concentration of nanoparticles at the dotted black line location. Both the velocity 
and magnetic dominated case have a nearly uniform nanoparticle concentration (note the zoomed in 0.99 to 1.01 concentration scale for 
cases [A & B] versus the log scale for case [C]). The focusing magnet is located at the bottom and pulls nanoparticles towards it. Only in 
the boundary layer case does a distinct concentration build-up occur and the concentration within the tissue exceeds that of the blood 
vessel. The velocity dominated case does not easily allow particles to enter the tissue due to the constant movement of particles out of 
the blood vessel. The magnetic dominated case allows particles to enter the vessel membrane and tissue space but does not concentrate 
them within the vessel membrane or tissue. Only the boundary layer case enables particles to significantly concentrate within the vessel 
membrane and tissue space.  
See [11] for more details.
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(including both extravasation and scattering 
by blood cells [9,10]), and from the pull of the 
applied magnetic fields. The Richardson, Péclet, 
and Renkin numbers quantify the competition 
between these three effects (equationS 3–6). 
Our simulations revealed the three types 
of behavior shown in Figure 3. In the velocity­
dominated case, the created magnetic forces are 
weak compared with the blood flow forces, so 
they cannot capture the particles and, therefore, 
the nanoparticles are washed out the back of 
the blood vessel. In the magnetic­dominated 
case, the magnetic forces far exceed the abil­
ity of the vessel membrane and tissue to resist 
particle motion, to the point where the parti­
cles are pulled by the magnet out of the vessel 
and, eventually, also out of the region of tis­
sue being considered. This case either requires 
exceedingly strong magnetic forces, or a blood 
vessel membrane that does not substantially 
inhibit particle movement (e.g., a sufficiently 
‘leaky’ tumor vessel). In the boundary­layer 
case, nanoparticles accumulate in a layer at the 
vessel wall and, if extravasation is possible, are 
Figure 4. The behavior of nanoparticles for varying richardson and renkin numbers at a 
fixed Péclet number (corresponding to the rat capillary example). The three behavior domains 
are shown: velocity dominated on the left, boundary layer on the right (with a continuous transition 
region between them) and a strip of magnetic dominated cases at the top for Renkin numbers near 
unity. For any Richardson and Renkin pair, the predicted nanoparticle behavior is determined by 
looking up that (Richardson, Renkin) point on the graph and seeing which region it falls into. Note 
that the minimum of the endothelium and tissue Renkin numbers determines the type of behavior 
and so it is this quantity that is used on the vertical axis. The rat capillary example is marked by the 
green circle.
then in the correct location to enter the sur­
rounding tissue. It is this last case that is most 
interesting and effective for drug delivery, as 
the applied magnetic field serves to concentrate 
the therapeutic. 
To understand which behaviors occur, and 
when, we first show a case for a fixed Péclet 
number of Pe = 1000 (Figure 4), as corresponds 
to our previous rat capillary example. For each 
(Richardson–Renkin) pair, it shows which 
behavior is occurring. The behavior switches 
from velocity­dominated to boundary­layer 
cases as the Richardson number increases, but, 
as seen from the plot, and described earlier, this 
transition can happen well before the magnetic 
forces attain the value of blood drag forces at the 
vessel centerline. For Pe = 1000, the boundary­
layer behavior begins when Y exceeds 5 × 10­5 
(i.e., when the magnetic forces have reached 
just 0.005% of the centerline drag forces). The 
transition from the velocity to boundary­layer 
behavior is gradual, so we show the delineation 
between them as a ‘fuzzy’ border. This transition 
is delayed as the Renkin number increases (the 
The Ψ
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angled border at the top of the plot) because, if 
diffusion in the endothelium and tissue is high, 
any build­up of particles in the tissue can diffuse 
more easily back out into the vessel, and then be 
swept away by blood flow. For the rat capillary 
example, Figure 4 allows us to read how much 
magnetic force is necessary to achieve magnetic 
focusing – from the log scale, the magnetic force 
applied should be greater than 0.005% of the 
centerline blood drag force.
The work f low for utilizing the predic­
tive capabilities of this method is outlined in 
Supplementary Figure 1 (www.futuremedicine.com/
doi/suppl/10.2217/nnm.10.104). Initially, 
the researcher should determine the variables 
involved in the experiment. Then they should 
calculate the parameters necessary for determin­
ing the nondimensional numbers using the equa­
tions provided. Finally, knowing the nondimen­
sional numbers associated with the experiment 
enables the researcher to predict the nanoparticle 
behavior within the specific e xperimental set­up.
Figure 5 provides the dependence on all three 
nondimensional numbers, as well as a com­
parison against the five available prior in vitro 
and in vivo experimental studies of magnetic 
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Figure 5. The experimental domains of prior studies plotted on a 3d representation of the nondimensional number space 
versus our predictions. The shaded regions show the three behavior types: magnetic dominated against the back in blue; velocity 
dominated at the bottom left (the curved green ramp shape); and boundary layer formation everywhere else (in white). The in vitro 
experiments are shown as small boxes [14,16]; the in vivo experiments are shown as large colored wireframes (the two boxes and the 
extruded curved triangle) [1,5,15]. Regions where the experiments leave the boundary layer formation region and enter the velocity 
dominated region are denoted by translucent shading (seen in the Lübbe, Widder and Bergemann cases, Ganguly and Xu remain wholly 
in the boundary layer domain). The outlined shapes cover the range of cases expected in the experiments. In all cases, the observed 
absence or presence of magnetic drug focusing matched our theoretical predictions. All of these experiments were designed to be 
successful and they all largely lie in the boundary build-up domain, although for Lübbe [1] there are deeper vessels with faster blood 
flows which fall into the velocity dominated case. Our analysis correctly predicted when those situations occurred. 
See [11] for a more detailed version of this figure.
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executive summary
  Our objective was to predict which blood vessels, and surrounding tissue, can (or cannot) be reached by magnetic drug targeting. 
  Governing equations describing particle transport in vivo under applied magnetic fields were reduced to depend upon a minimal 
number of nondimensional numbers: the magnetic-Richardson, Péclet and Renkin numbers.
  Across all physiological conditions, and for achievable engineering conditions, behavior was found to fall into one of three categories: 
velocity-dominated, magnetic-dominated or boundary-layer behavior (the desired case, corresponding to a focusing of the nanoparticles 
by magnetic forces).
  The type of behavior was uniquely predicted by our three nondimensional numbers. A complete mapping was provided, which showed 
which behavior occurred when.
  The predictions made were in excellent agreement with both in vitro and in vivo prior published magnetic focusing studies, indicating 
that our method provides an effective way to forecast magnetic drug delivery behavior in and around vessels.
focusing. Each study had a range of nondi­
mensional numbers associated with it. In vitro 
studies typically had a small range, owing to 
tightly controlled experimental conditions. 
In vivo studies had a larger spread, since a range 
of organism parameters must be considered, 
encompassing small and large, shallow and 
deep blood vessels with a wide physiological 
range of blood flow velocities. Based on this, 
shapes could be drawn that outline the range 
of parameters in each animal or human experi­
ment (details in [11]). Figure 5 shows the ranges for 
each study against our predicted behaviors. In 
all cases, we found that, when magnetic focusing 
was observed (or not), in the in vitro cases, or to 
certain depths for slow or fast blood flows in the 
human and animal experiments, it matched our 
predictions. We were able to correctly predict 
both the occurrence and amount of magnetic 
capture in in vitro experiments (even in a case 
where the standard force comparison failed, 
thus resolving an open question noted by the 
authors [14]). For in vivo experiments we cor­
rectly predicted observed particle accumulation 
in rats [5,15], as well as the depth of focusing 
(~5 cm) in a human head­and­neck tumor (as 
was measured by MRI after the treatment) [1]. 
Thus, our analysis provides an accurate way of 
predicting behavior across the range of physi­
ological and expected engineering parameters 
and, as such, it should be a valuable tool for 
the design of next­generation magnetic drug 
d elivery systems.
Future perspective
Magnetic drug delivery is emerging as a power­
ful drug­targeting option, with the ability to 
physically direct therapeutics to sites of dis­
ease [1,4,6]. The design of effective magnetic 
drug delivery systems is an endeavor that must 
match engineering to physiology and, as such, 
it requires an ability to understand and predict 
how engineering choices (e.g., particle size and 
composition, magnet placement, shape and 
strength) affect drug distribution in vivo. This 
cannot be achieved through animal experiments 
alone – the number of animals that would be 
required to exhaustively search the design space 
is staggering – and current simple back­of­the­
envelope analyses have proved insufficient. 
Thus, there is a broad need for the type of 
modeling conducted by our group. Although 
physiological behavior is complex, and predict­
ing it is a great challenge, our current analysis is 
a sensible next step – it uses physical first prin­
ciples and available physiological information, 
and is effective. Weak points of the modeling 
must now be identified, such as our simple 
treatment of extravasation as diffusion [9], and 
should be rank ordered (to assess which weak­
nesses should be addressed first to improve the 
predictions and enable better design of next­ 
generation magnetic drug delivery systems) 
and, then, in vitro and animal experiments must 
be devised to isolate, understand, measure and 
fix the weaknesses. For example, we are cur­
rently creating experiments to precisely measure 
particle transport through excised tissue and 
blood vessel walls under carefully applied mag­
netic forces to quantify diffusion and extravasa­
tion. The suite of tools that we will build will 
teach us a great deal about the behavior of nano­
particles in vivo, and will enable better design 
and optimization of next­generation magnetic 
drug delivery systems.
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Magnet Parameters 
Magnet strength 
Magnet dimensions 
MMM hwL 
B
Distance from magnet 
to target 
d
[Tesla] 
[meters] 
[meters] 
Particle Parameters 
Magnetic core radius1 
Hydrodynamic 
diameter 
Particel material 
magnetic susceptibility 

hydrod
a [meters] 
[meters] 
In-vivo Parameters 
Pore sizes for tissue 
and membrane 
Max blood speed 
Blood vessel diameter 
maxBV
Bd
mempd ,
Blood viscosity 

tisspd , [meters] 
[meters/second] 
[meters] 
[Pascal seconds] 
m 1)0.050.005.0(  MMM hwL
m001.0d
m10125 9a
20
T5.0B
m/s0001.0max BV
sPa003.0 
m10250 9hydrod
m106 6Bd
K310T
m10600 9,
mempd
m10600 9,
tisspd
Body temperature 
T [Kelvin] 
Start by establishing the following variables, which include magnet, particle 
and in-vivo parameters. The magnetic field experienced at the target location is 
determined by the magnet strength, the dimensions of the magnet, and the 
distance from the magnet. The composition of the particles determines the 
magnetic core radius, hydrodynamic diameter, and magnetic susceptibility. The 
location of the target region within the body determines the type of tissue, 
target depth, and the proximity, size and type of blood vessels [10-11]. 
Below are the parameters for the rat 
example in Figure 2. The membrane 
pore diameters correspond to leaky 
tumor vessels. 
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Use modeling software to 
compute the magnetic 
field and its derivative. 
Magnet Field Magnetic Force 

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Compute the magnetic force 
using equation (4) from [12] 
Stokes Drag Force 
max3 BhydroS VdF 

Diffusion Coefficients 
Calculate the blood 
diffusion coefficient: 
Calculate membrane and 
t i s s u e  d i f f u s i o n 
coefficients using [10,11] 
a
Tk
D BB
6

Calculate scattering 
coefficient (DS) in SI 
units [m2/s] using [10]. 
C a l c u l a t e  t o t a l 
coefficient: 
SBTot DDD 
   
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Using the parameters established in Step 1, the following equations can 
calculate the forces and diffusion coefficients necessary to predict the 
ferrofluid behavior. The magnetic field and gradient are to be evaluated at the 
target position (x*,y*,z*) from a simulated or measured magnetic vector field. 
Then calculate the magnetic force. Determine the Stokes drag force by the 
blood flow speed at the target location. The diffusion coefficients are 
calculated for the corresponding target region in the biological system. 
By COMSOL2: 
The stokes drag force is for a 
capillary near tumors. 
The diffusion coefficients are 
associated with leaky capillaries near 
tumors. As noted in [11], the scattering 
coefficient is not applicable. 
N101 13

 MdirectionyM
FF

)m/s0001.0)(sPa003.0)(m10250(3 9 SF

Given the blood flow speed 
at the target location, 
compute the Stokes drag: 
Evaluate at the target 
location (x*,y*,z*) that is 
located a distance d from 
the magnet. 
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RICHARDSON NUMBER 
MASS PECLET 
NUMBER 
S
M
F
F

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D
Vd maxPe
RENKIN DIFFUSION 
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From the variables calculated in Step 2, determine the following four non-
dimensional numbers. Using these four non-dimensional numbers, the 
coordinate location within the non-dimensional space can be determined. This 
location will reveal the ferrofluid behavior. 
)),min(, TDDPe
The four non-dimensional numbers are 
Check that forces are in SI 
units [Newtons]. 
The rat capillary example falls into the 
boundary layer formation region. 
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Supplementary Figure 1:  The process flow for determining the ferrofluid behavior in and around a blood vessel under an 
external magnetic field. With step 1 the critical parameters are established; step 2 calculates the required variables from the described 
formulas; and step 3 predicts the ferrofluid behavior based upon the four non-dimensional numbers derived from the calculated variables. 
All units are in standard international (SI) format. Double bars (|| · ||) denotes the Euclidean norm of a vector. Brackets within equations 
([ · ]) denote a vector or matrix quantity.  denotes the gradient operator. 1The magnetic core radius is the radius of the region enclosing 
the magnetic components of the magnetic particle. 2When developing the theoretical model to predict the magnetic field and its derivative, 
it is beneficial to take advantage of the symmetry inherent within in the problem. In our convention, we align the blood vessel with the x-
axis and consider a magnet placed symmetrically along the y axis. 
